Skip to main content
. 2007 Oct 1;9(10):760–769. doi: 10.1111/j.1524-6175.2007.07244.x

Table III.

Most Commonly Reported Adverse Eventsa

Adverse Event Patients, No. (%)
Darusentan (n=76) Placebo (n=39)
Peripheral edema 13 (17) 2 (5)
Headache 8 (11) 2 (5)
Sinusitis 6 (8) 0
Dizziness 5 (7) 1 (3)
Nasopharyngitis 5 (7) 1 (3)
Upper respiratory tract infectionb 4 (5) 2 (5)
Gastroenteritis 4 (5) 1 (3)
Arthralgia/arthritis 2 (3) 6 (15)
Diarrhea 1 (1) 2 (5)
aOccurred in ≥5% of patients in a treatment group. bIncluded patients with symptoms of an upper respiratory tract infection.